BioCryst Pharmaceuticals Inc. (BCRX)

3.39
NASDAQ : Health Technology
Prev Close 3.48
Day Low/High 3.38 / 3.52
52 Wk Low/High 2.80 / 9.95
Avg Volume 2.26M
Exchange NASDAQ
Shares Outstanding 110.31M
Market Cap 383.89M
EPS -1.00
P/E Ratio N/A
Div & Yield N.A. (N.A)
Cel-Sci Fuzzy With Details of H1N1 Drug Test

Cel-Sci Fuzzy With Details of H1N1 Drug Test

Has the FDA granted Cel-Sci permission to test its H1N1 flu drug in patients? Hard to say, apparently.

Cell Therapeutics' Opaxio Data Not Terrible: BioBuzz

Cell Therapeutics' Opaxio Data Not Terrible: BioBuzz

More work needs to be done before penciling in approval.

The Long Trade on Chelsea Therapeutics: BioBuzz

The Long Trade on Chelsea Therapeutics: BioBuzz

Risk-reward for this beaten-down stock improves as pivotal study results loom.

BioCryst Updates the Obvious: BioBuzz

BioCryst Updates the Obvious: BioBuzz

The flu drug company's response to government was widely expected.

Spectrum Heeds Biotech's Golden Rule: BioBuzz

Spectrum Heeds Biotech's Golden Rule: BioBuzz

Raise money when you can it, not when you need it.

BioCryst and the Financially Limber Analyst: BioBuzz

BioCryst and the Financially Limber Analyst: BioBuzz

One analyst uses valuation acrobatics to retain his BioCryst price target.

Nexavar Side Effect Affects Onyx Trading: BioBuzz

Nexavar Side Effect Affects Onyx Trading: BioBuzz

Higher rates of hand-foot syndrome reported in breast cancer study

Rose-Colored Math Required for BioCryst Bull Case: BioBuzz

Rose-Colored Math Required for BioCryst Bull Case: BioBuzz

The U.S. government's purchase of peramivir is not likely to yield big profits.

BioCryst Flu Drug Request Below Expectations

U.S. government seeks to stockpile small amount of peramivir for hospitalized flu patients

Bulls, Bears Fight Over BioCryst: BioBuzz

Bulls, Bears Fight Over BioCryst: BioBuzz

Analyst's lukewarm report sends shares lower

BioCryst Warns Peramivir Sales May Not Bring Profits: BioBuzz

BioCryst Warns Peramivir Sales May Not Bring Profits: BioBuzz

Flu drug maker's small but perhaps important change to its disclosures

Dueling Views of Arena Pharma: BioBuzz

Dueling Views of Arena Pharma: BioBuzz

Bulls and bears prepare for Arena Pharma's obesity drug trial results.

BioCryst Still Waiting for Flu Drug Deals: BioBuzz

BioCryst Still Waiting for Flu Drug Deals: BioBuzz

No government contracts for peramivir stockpiling signed yet

Swine Flu Biotech Bubble Primed to Burst

Swine Flu Biotech Bubble Primed to Burst

Biotech stocks playing in the influenza space have soared since the dawn of swine flu. Now, as the fall flu season arrives, can those stocks still perform?

Biocryst Flu Drug Missing From CDC Guidelines: BioBuzz

Biocryst Flu Drug Missing From CDC Guidelines: BioBuzz

Investors waiting for government to buy emergency stockpile of peramivir

Biotech Mailbag: Biocryst, Anadys, Allos, Amag

Readers weigh in on Biocryst's flu drug, the forecast for Alzheimer's drugs, Allos' prognosis, and why AMAG's stock is getting pummeled.

Biotech's Hot and Getting Hotter

Biotech's Hot and Getting Hotter

July and August are traditionally slow months on the biotech calendar. But not this year as biotech firms, both big and small, release results from clinical trials or await FDA decisions.

Biotech Stock Mailbag: Discovery Labs

Readers sound off on Discovery Labs, Micromet and BioDelivery.

Stockpickr's Charts of the Day: Nasdaq Stocks

Stockpickr's Charts of the Day: Nasdaq Stocks

Here's a look at the charts of Nasdaq stocks such as Cheesecake Factory and BioCryst.

BioCryst Shares Surge on Flu Study

BioCryst says that its intravenous flu drug showed positive results in study, sending its shares surging 40%.

China Watch Podcast: Honing in on Gold Horse

China Watch Podcast: Honing in on Gold Horse

This week, Adam Wasserman, CFO of Gold Horse International, explains this multi-faceted business group that specializes in high-growth industries in China, and reveals the company's plans within the wind power industry and what the real estate development and construction scene in China looks like right now. Also, Elsa Sung, CFO of Jiangbo Pharmaceutical, gives us the latest on the company, its recently-reported results for the third quarter of its fiscal year 2009, the acquisition of Hong Rui and how she expects the company to grow in the coming year. And, Stephanie Link, director of research for Action Alerts Plus, says this may be a time of opportunity to get in on a more pure China play - Dow Chemical. She explains why this is such an opportune time for this stock, what exciting moves Dow is making, and how you can play it. Finally, one viewer is looking for a mutual fund that encompasses all of the many Chinese Internet stocks that are growing so rapidly.

Tiny Biotechs Dancing in the Bull Pen

Tiny Biotechs Dancing in the Bull Pen

Itty bitty biotechs are big again, thanks to the H1N1 virus, cancer drug abstracts, and Vanda's recent success.

YRC Worldwide, AIG, Blockbuster Are Big Movers

YRC Worldwide, AIG, Blockbuster Are Big Movers

YRC Worldwide, AIG, Blockbuster, Chemed, First Energy among big market movers Friday

BioCryst Shares Rise Ahead Of Study Data

BioCryst Shares Rise Ahead Of Study Data

BioCryst Pharmaceuticals shares rise, company 'encouraged' by upcoming study data

Biotech Rocket Stocks for the Week

Biotech Rocket Stocks for the Week

These stocks could surge higher (or lower) in the coming days.

BioCryst Says Flu Drug Candidate Failed In Trial

BioCryst Says Flu Drug Candidate Failed In Trial

BioCryst slides after intramuscular peramivir caused little improvement in midstage trial

Mexcian Swine Flu Plays

Here's how to trade the swine flu as panic peaks and eases, with an emphasis on Mexican stocks.

Four Must-See Charts: Biotech Stocks

These speculative biotech stocks could be setting up to make significant moves in the near future.

Swine Flu Outbreak: Photo Gallery

Swine Flu Outbreak: Photo Gallery

Top Health Care Short-Squeeze Plays

These heavily shorted health care stocks could surge higher on any positive catalyst.

TheStreet Quant Rating: D- (Sell)